Supplier News

Oct 30, 2017
By BioPharm International Editors
Wyatt Technology has added the DynaPro Plate Reader III to its macromolecular and nanoparticle characterization product offerings.
Oct 30, 2017
By BioPharm International Editors
The biotechnology company has entered a contract with the United States Army to develop custom recombinant spider silk for protective textile applications.
Oct 26, 2017
By BioPharm International Editors
The company has opened new facilities and an innovation center in Singapore, China that will focus on the development of plant-based products.
Oct 25, 2017
By BioPharm International Editors
ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility.
Oct 25, 2017
By BioPharm International Editors
Catalent’s new Biologics & Specialty Drug Delivery unit will be led by Barry Littlejohn; Jonathan Arnold to lead Oral Drug Delivery.
Oct 24, 2017
By BioPharm International Editors
The API manufacturer has announced that it has completed the expansion of large-scale manufacturing capabilities at its Charles City, Iowa site.
Oct 24, 2017
By BioPharm International Editors
The biopharmaceutical company has received a $4.2-million grant from the Bill & Melinda Gates Foundation to invest in the development of new treatments for Enterotoxigenic Escherichia coli infections, a bacterial cause of diarrhea in the developing world.
Oct 23, 2017
By BioPharm International Editors
The biotechnology company has officially opened its new Michigan research and production center for the production of spider silk-based fibers, as well as for the company’s polymer research and development program.
Oct 23, 2017
By BioPharm International Editors
The clinical-stage biopharmaceutical company has announced the opening of a new gene therapy manufacturing facility in Modiin, Israel, which is anticipated to be the production site of the company’s lead cancer drug candidate.
Oct 20, 2017
By BioPharm International Editors
The companies will embark on a joint antimicrobial research project, with the intent to discover antibiotic combinations that target resistance.
native1_300x100
lorem ipsum